Neotonus began manufacturing and marketing devices using its ExMI technology in September 1998 for the treatment and management of urinary incontinence. To date, the company has focused its efforts on its NeoControl® Pelvic Floor Therapy System developed to treat the most common causes of urinary incontinence. Since FDA approval in June 1998, NeoControl has been used in more than 225 urology, obstetrics/gynecology and physical therapy practices throughout the United States and 47 other countries to deliver more than 1 million treatments, with no reported adverse side effects.

Over 17 million Americans currently suffer from incontinence and over 16 billion US healthcare dollars were spent for the management of incontinence in 1998. To date, over 50,000 patients have been treated with the NeoControl Therapy.

The company holds a broad range of patents for its pulsed magnetic technology (ExMI) for medical applications. The patents are based on the unique ability of ExMI technology to focus its high energy pulses to penetrate deeply into tissue, without pain or side effects.